MedTrace Logo

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

NCT02523690 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-01-13

Study results available
· View outcomes & findings →

Summary

ICU acquired muscle weakness is a significant problem in patients recovering from critical illness. This trial will evaluate the safety and efficacy of a drug in improving muscle weakness in critically ill patients.

Conditions

Interventions

DRUG

Lorcaserin

10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later

DRUG

Placebo

Oral or enteral, single dose. Oral or enteral, single dose two days later

Sponsors & Collaborators

Principal Investigators

  • Dale M Needham, MD, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02523690 on ClinicalTrials.gov